Acetazolamide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1953
- First approval year
- 1953
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Acetazolamide
- Molecular weight
- 222.25
- Structure (SMILES)
- CC(=O)Nc1nnc(S(N)(=O)=O)s1
- acetazolamide
- Acetazolamide
- diamox
- Diamox
- diamox sr
- Diamox sr
- eytazox
- Eytazox
- acetamox
- Acetamox
- acetazolamida
- Acetazolamida
- acetazolamide
- Acetazolamide
- ACETAZOLAMIDE [EP IMPURITY]
- ACETAZOLAMIDE [EP MONOGRAPH]
- ACETAZOLAMIDE [HSDB]
- acetazolamide [INN]
- ACETAZOLAMIDE [JAN]
- ACETAZOLAMIDE [MART.]
- ACETAZOLAMIDE [MI]
- ACETAZOLAMIDE [ORANGE BOOK]
- ACETAZOLAMIDE [USP MONOGRAPH]
- ACETAZOLAMIDE [USP-RS]
- ACETAZOLAMIDE [VANDF]
- Acetazolamide [WHO-DD]
- ACETAZOLAMIDE [WHO-IP]
- acetazolamide 125 mg
- Acetazolamide 125 mg
- acetazolamide 250 mg
- Acetazolamide 250 mg
- acetazolamide 62 5 mg
- Acetazolamide 62.5 mg
And 41 more, listed on the interactive page.
- ATC classification codes
- S01EC01
Sources for recorded values
- CAS registry numbers
- 59-66-5
- ChEMBL ID
- CHEMBL20
- InChIKey
- BZKPWHYZMXOIDC-UHFFFAOYSA-N
- PubChem compound IDs
- 1986
- RxNorm IDs (RxCUI)
- 167
- FDA ingredient codes (UNII)
- O3FX965V0I
- Applicant
- TEVA BRANDED PHARM
- Approval date
- 27 Jul 1953
- Application number
- NDA008943
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- acetazolamide
- Type
- Synthetic organic
- Drug name stem
- -zolamide
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- carbonic anhydrase 12
- Gene symbol
- CA12
- Protein identifier
- O43570
- Median affinity
- 8.24
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- carbonic anhydrase 1
- Gene symbol
- CA1
- Protein identifier
- P00915
- Median affinity
- 6.6
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- carbonic anhydrase 4
- Gene symbol
- CA4
- Protein identifier
- P22748
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- carbonic anhydrase 7
- Gene symbol
- CA7
- Protein identifier
- P43166
- Median affinity
- 8.6
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- carbonic anhydrase 14
- Gene symbol
- CA14
- Protein identifier
- Q9ULX7
- Affinity units
- pKi
- Mechanism
- Carbonic anhydrase I inhibitor
- Action type
- Inhibitor
- Target
- Carbonic anhydrase 1
- Protein identifier
- P00915
- Mechanism
- Carbonic anhydrase II inhibitor
- Action type
- Inhibitor
- Target
- Carbonic anhydrase 2
- Protein identifier
- P00918
- Mechanism
- Carbonic anhydrase IV inhibitor
- Action type
- Inhibitor
- Target
- Carbonic anhydrase 4
- Protein identifier
- P22748
- Mechanism
- Carbonic anhydrase XII inhibitor
- Action type
- Inhibitor
- Target
- Carbonic anhydrase 12
- Protein identifier
- O43570
- Mechanism
- Carbonic anhydrase I inhibitor
- Action type
- Inhibitor
- Target
- Carbonic anhydrase 1
- Mechanism
- Carbonic anhydrase II inhibitor
- Action type
- Inhibitor
- Target
- Carbonic anhydrase 2
- Mechanism
- Carbonic anhydrase IV inhibitor
- Action type
- Inhibitor
- Target
- Carbonic anhydrase 4
- Mechanism
- Carbonic anhydrase XII inhibitor
- Action type
- Inhibitor
- Target
- Carbonic anhydrase 12
- Action type
- Inhibitor
- Gene symbol
- CA12
- Protein identifier
- O43570
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- CA1
- Protein identifier
- P00915
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- CA2
- Protein identifier
- P00918
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- CA4
- Protein identifier
- P22748
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Heart Failure
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Epilepsy
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000474
- Subject identifier
- D004827
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001361
- Subject identifier
- D006976
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002617
- Subject identifier
- D008545
- Condition
- Kidney Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Heart Failure
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Sleep Apnea, Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003918
- Subject identifier
- D020181
- Condition
- Hypotension, Orthostatic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005252
- Subject identifier
- D007024
- Condition
- Psychotic Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005411
- Subject identifier
- D011618
- Condition
- Cysticercosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007231
- Subject identifier
- D003551
- Condition
- Status Epilepticus
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008526
- Subject identifier
- D013226
- Condition
- Edema
- Highest recorded phase
- 4
- Condition identifier
- EFO:0009373
- Subject identifier
- D004487
- Condition
- Altitude Sickness
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000782
- Subject identifier
- D000532
- Condition
- Helicobacter Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000961
- Subject identifier
- D016481
- Condition
- Landau-Kleffner Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001010
- Subject identifier
- D018887
- Condition
- Hydrocephalus, Normal Pressure
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001065
- Subject identifier
- D006850
- Condition
- Pseudotumor Cerebri
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001132
- Subject identifier
- D011559
- Condition
- Seizures
- Highest recorded phase
- 4
- Condition identifier
- HP:0001250
- Subject identifier
- D012640
- Condition
- Apnea
- Highest recorded phase
- 3
- Condition identifier
- HP:0002104
- Subject identifier
- D001049
- Condition
- Chronic Pain
- Highest recorded phase
- 2
- Condition identifier
- HP:0012532
- Subject identifier
- D059350
- Condition
- Glaucoma, Angle-Closure
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0001744
- Subject identifier
- D015812
- Condition
- Macular Edema
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0003005
- Subject identifier
- D008269
And 7 more, listed on the interactive page.
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000373
- Condition identifier
- EFO_0000474
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000712
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001073
- Condition identifier
- EFO_0001361
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003877
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003918
- Condition identifier
- EFO_0005411
- Condition identifier
- EFO_0009373
- Condition identifier
- EFO_0009373
- Highest recorded phase
- 4
- Condition identifier
- EFO_0010143
- Highest recorded phase
- 1
- Condition identifier
- EFO_0010702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0803536
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000782
- Condition identifier
- EFO_1001065
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001132
- Highest recorded phase
- 3
- Condition identifier
- HP_0000556
- Highest recorded phase
- 2
- Condition identifier
- HP_0000572
- Highest recorded phase
- 2
- Condition identifier
- HP_0000822
- Highest recorded phase
- 2
- Condition identifier
- HP_0001250
- Condition identifier
- HP_0001250
- Highest recorded phase
- 4
And 56 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- dermatological toxicity
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Warning
- Black Box Warning
- Effect
- dermatological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Country
- United States
- Event
- acidosis
- Reports
- 18
- Reporting signal score
- 47.0407
- Event
- acidosis hyperchloraemic
- Reports
- 9
- Reporting signal score
- 39.3073
- Event
- angle closure glaucoma
- Reports
- 45
- Reporting signal score
- 191.698
- Event
- anterior chamber disorder
- Reports
- 7
- Reporting signal score
- 32.9613
- Event
- anuria
- Reports
- 9
- Reporting signal score
- 15.9208
- Event
- autism spectrum disorder
- Reports
- 5
- Reporting signal score
- 13.9647
- Event
- cataract subcapsular
- Reports
- 4
- Reporting signal score
- 13.3115
- Event
- cerebral venous sinus thrombosis
- Reports
- 4
- Reporting signal score
- 14.4024
- Event
- choroidal detachment
- Reports
- 34
- Reporting signal score
- 182.288
- Event
- choroidal effusion
- Reports
- 28
- Reporting signal score
- 137.862
- Event
- cognitive disorder
- Reports
- 15
- Reporting signal score
- 14.5398
- Event
- condition aggravated
- Reports
- 56
- Reporting signal score
- 32.7708
- Event
- confusional state
- Reports
- 29
- Reporting signal score
- 14.0099
- Event
- congenital emphysema
- Reports
- 7
- Reporting signal score
- 49.2313
- Event
- cross sensitivity reaction
- Reports
- 4
- Reporting signal score
- 15.1101
- Event
- crystalluria
- Reports
- 8
- Reporting signal score
- 32.3311
- Event
- dropped head syndrome
- Reports
- 4
- Reporting signal score
- 16.6003
- Event
- drug clearance decreased
- Reports
- 5
- Reporting signal score
- 14.4019
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 22
- Reporting signal score
- 29.6079
- Event
- dysmetria
- Reports
- 5
- Reporting signal score
- 18.052
- Event
- exposure via breast milk
- Reports
- 6
- Reporting signal score
- 15.1757
- Event
- eye oedema
- Reports
- 6
- Reporting signal score
- 16.2066
- Event
- flat anterior chamber of eye
- Reports
- 4
- Reporting signal score
- 16.3196
- Event
- glaucoma
- Reports
- 18
- Reporting signal score
- 37.2343
- Event
- grunting
- Reports
- 6
- Reporting signal score
- 24.3075
And 40 more, listed on the interactive page.
- NCT00000115
- NCT05290948
- NCT00223691
- NCT00485238
- NCT01228149
- NCT02390284
- NCT00634491
- NCT00746954
- NCT00839501
- NCT01003639
- NCT03501966
- NCT03963336
- NCT01187108
- NCT01418157
- NCT01993667
- NCT02604173
- NCT03154645
- NCT03424226
- NCT03536429
- NCT03536455
- NCT03536507
- NCT03536520
- NCT03537924
- NCT03539367
- NCT03540914
And 31 more, listed on the interactive page.
- Dose
- 500mg
- How often
- Twice daily
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 115.04
- Calculated partition coefficient (ALogP)
- -0.86
- Calculated partition coefficient (XLogP)
- -0.3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 13
- Molecular formula
- C4H6N4O3S2
- Monoisotopic mass
- 221.98813241
- Natural product
- Yes
- 0904-6663
- 10135-830
- 10135-831
- 16729-331
- 23155-287
- 23155-288
- 23155-787
- 27241-132
- 27241-133
- 42291-089
- 42291-090
- 42571-243
- 46708-349
- 50268-042
- 50268-054
- 50742-233
- 51655-331
- 52817-200
- 52817-201
- 59651-905
- 59651-906
- 60687-578
- 62135-607
- 62135-608
- 62135-612
And 40 more, listed on the interactive page.
- Recorded assays
- 10,393
- Active assays
- 3,146
- Confirmatory
- Other
- Screening
- Summary
- Anticonvulsants
- Carbonic Anhydrase Inhibitors
- Diuretics
These details could not be displayed.
Related records
Trials (151)
- A Combined Surgical and Medical Approach in Mild Sleep Apnea
- A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning
- A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction
- A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing
- A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent
- Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome
- Acetazolamide Add-On Therapy to OSA Surgery
- Acetazolamide and Exercise Performance at Altitude
- Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA
- Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm
- Acetazolamide Efficacy in Ataxia in PMM2-CDG
- Acetazolamide Facilitates Ventilator Weaning
- Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health
- Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis
- Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing
- Acetazolamide for the Prevention of Post Operative CSF Leak
- Acetazolamide for Treating NPH in Shunt-candidates Patients
- Acetazolamide for Treatment Resistant Schizophrenia
- Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
- Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)
Approved for (7)
- Altitude sickness
- Angle-closure glaucoma
- Congestive heart failure
- Epilepsy
- Glaucoma
- Heart failure
- Visual epilepsy
In development for (40)
- Andersen-Tawil syndrome Phase 1
- Astrocytoma (excluding glioblastoma) Phase 1
- Central sleep apnea syndrome Phase 2
- Cerebellar ataxia Phase 2
- Chronic obstructive pulmonary disease Phase 3
- Cysticercosis Phase 2
- Cystoid macular edema Phase 2
- Developmental and/or epileptic encephalopathy with spike-wave activation in sleep Phase 2
- Glioblastoma Phase 1
- Helicobacter pylori infectious disease Phase 2
- Hepatocellular carcinoma Phase 3
- Hypertensive disorder Phase 2
- Inherited retinal dystrophy Phase 2
- Kidney disorder Phase 2
- Landau-Kleffner syndrome Phase 2
- Macular retinal edema Phase 2
- Melanoma Phase 1
- Metastatic melanoma Phase 1
- Multiple sclerosis Phase 2
- Normal pressure hydrocephalus Phase 3
Other linked conditions (8)
- Bartter syndrome
- Chronic kidney disease
- Headache disorder
- Intracranial hypertension
- Migraine disorder
- Obesity disorder
- Potassium deficiency disease
- Sickle cell disease